BSG BioNewsLetter 03#2002

Anna Johansson anna.johansson at
Tue Sep 3 14:25:24 EST 2002

BSG BioNewsLetter 03#2002 - BioSeeker Group's analysis and products eNewsletter



1) Ion Channel HTS - Mission Impossible?
2) The Swedish BioTech Corporate Index - A new service from BioSeeker Group
3) Coming reports: Swedish Pharma Industry / The Next Generation of Antifungals
4) New Reports: Tumor Antigens / Ion Channel Assays / Gene Therapy
5) Subscription
6) Conference Opportunity



Ion channels are significant targets in the drug discovery process, generating over 8 billion dollars in sales per annum. In  2000, the FDA approved fourteen new drugs targeting ion channels. Considering the publication of the human genome and the ability of transcription profiling to reveal tissue specific distribution, it is expected that ion channels will play an even more important role as drug targets in the future. Based on the demand for screening large compound collections against an increasing number of therapeutic targets there is an urgent requirement to develop automation, miniaturization and high throughput assay systems. This requires the development of homogenous assay formats and higher detection sensitivity.

Read the full version of this free, analytical BioNewsletter article at



The Swedish BioTech Corporate Index makes it easy to find information on almost any Swedish biotech company. The Index contains 379 companies, sorted into 16 industry segments. Our databases are updated both through the companies' own participation and by BioSeeker GroupÕs researchers, making our database the most up-to-date and extensive in the world. To learn more about our Swedish Biotech Company Profiles and browse the companies included in the index, please visit



- Swedish Pharma Industry (to be released Sept 9, 2002)

Sweden is one of the worldÕs most densely populated countries when it comes to analyzing the global biotechnology market. With less than 9 million inhibitants, there are more than 350 biotech companies in Sweden. In our coming report, BioSeeker Group analyzes in detail all pharmaceutical biotechnology firms in Sweden. The report covers industry focus on different disease groups, collborations, financial data, pipeline information and much more. The analysis deals with status, development, direction, strategy and position. The report also includes extensive profiles of all 70 pharmaceutical biotechnology firms in Sweden. BioSeeker Group has more than 3 years of contineous research and analysis experience in Swedish biotech industry. Anything similar cannot be found in any other company or organization.

For more information about this report, please visit

- The Next Generation of Antifungals (to be released Oct, 2002)

According to the Antifungal Work Group at NIH there is a "critical need for the development of antifungal agents" (Draft report of the Antifungal Working Group Sep. 2000). "There is not a single rapidly fungicidal, non-toxic drug available", they continue, and it is a requirement for fungicidal, broad spectrum, non-toxic, orally deliverable drugs to have a low cost. We have identified more that 100 companies with interest in this field. The new report will provide you with an extensive update on the advancements of new antifungal therapies and give you an objective assessment to assist in your decision making process.
For further information about this report, please send us an email to bioinfo at 

For further reading about antifungals, please visit our free analytical article on this topic (



- Ion Channel Assays in the Drug Discovery Process (released June, 2002)

- Commercializing on Tumor Antigens: Analytical Perspectives (released Feb, 2002)

- The Competitive Landscape of Cancer Gene Therapy (released May, 2002)



To continue to stay tuned with coming editions of BioSeeker Groups BioNewsLetter, please send an email to subscribe at



BioNetwork 2002 is the premier  bio-partnering event for biotech and pharma business development and licensing executives worldwide. With a unique structure of industry case studies, roundtable discussion groups and one-to-one meetings, attendees will hear the partnering strategies of big pharma through to mid-sized biotechs and enjoy over 17 hours of both formal and informal networking.  So, to meet  200 senior business development and licensing professionals from over 15 countries and hear from  industry leaders such as: Immunex, Millenium, Novartis, Johnson & Johnson, Schering, CAT, Vertex and Oxford Glycoscienes, book your place now! 

For more information, please visit or contact Jonathan Ballantine (jonathan5 at


Do you have a message that you would like the biotech community to know? BioSeeker Group's Newsletter targets managers, scientists, venture capitalists, consultants and many more world wide. Contact us at sales at for further information on how to advertise in BSG BioNewsletter.


If you would like to comment on our newsletter please send us an email to feedback at

If you would like to be removed from our newsletter list, please reply to unsubscribe at


This message has been sent using for Win trial.


More information about the Cellbiol mailing list